heading

Media & Press

Read about our publications and press news.

heading

Press & News

Latest News

OncoX inks licensing deal worth over $26m for NSCLC therapy

US-based ABVC BioPharma has sold the rights to its botanical drug extract therapy, BLEX 404, for the treatment of non-small cell lung cancer (NSCLC) to the dietary supplements company OncoX.

Read More
Latest News

ABV-1519 for Non-Small Cell Lung Cancer (NSCLC)

Under the terms of the agreement, ABVC grants OncoX exclusive rights for one of ABVC's four products in its Oncology pipeline to develop, manufacture, and commercialize BLEX 404, a promising therapeutic agent for the treatment of NSCLC.

Read More
Leave a message

Need Assistance?